StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Merck (MRK) Strength Pre-Open Tied to Atea Pharmaceuticals Inc. (AVIR) Trial Missing Primary Endpoint
October 19, 2021 7:09 AM
Merck (NYSE: MRK) Strength Pre-Open ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Trader Talk
Next Articles
CDC ACIP Unanimously Votes to Recommends Merck's (MRK) VAXNEUVANCE in Series with PNEUMOVAX as Option for Pneumococcal Vaccination in Appropriate Adults
October 21, 2021 5:43 AM
Merck (MRK) Announces Voluntary Nationwide Recall of CUBICIN 500mg, Due to Presence of Particulate Matter Identified as Glass Particles
October 20, 2021 5:42 AM
Atea Pharmaceuticals (AVIR) Strong Sell-Off 'Premature' - William Blair
October 19, 2021 10:55 AM
Atea Pharmaceuticals Inc. (AVIR) to Resume Trading at 7:30 a.m.
October 19, 2021 7:10 AM
Atea Pharmaceuticals Inc. (AVIR) Phase 2 MOONSONG Trial Evaluating AT-527 in the Outpatient Setting Did Not Meet the Primary Endpoint
October 19, 2021 7:02 AM
Atea Pharmaceuticals Provides Update and Topline Results for Phase 2 MOONSONG Trial Evaluating AT-527 in the Outpatient Setting
October 19, 2021 7:00 AM
